Rolf I. Skotheim
Papers
1
Total Citations
30
H-Index
1
About
Rolf I. Skotheim is a leading cancer researcher whose work sits at the intersection of genomics, epigenetics, and immunotherapy, with a primary focus on prostate cancer. He is best known for pioneering the use of personalized dendritic cell (DC) vaccines as adjuvant therapy for high-risk prostate cancer patients. His landmark long-term Phase I/II study, published in 2021 and cited over 30 times, demonstrated the safety and feasibility of administering a patient-specific DC vaccine after radical prostatectomy to reduce the risk of biochemical relapse. This work represents a significant step toward harnessing the immune system to prevent recurrence in patients with aggressive disease. Beyond this clinical trial, Skotheim has made foundational contributions to understanding the molecular pathology of prostate cancer, including the discovery of recurrent gene fusions and epigenetic alterations that drive tumor progression. His research has been widely cited, reflecting its impact on both translational oncology and basic cancer biology. Skotheim’s work continues to shape the development of precision immunotherapies for solid tumors, offering new hope for patients with high-risk disease.
Research Focus
Key Achievements
Top Papers
- 1